ma multiplex, pyoderma vegetans, and pityriasis rubra pilaris (6) (7) (8) (9) (10) (11) (12) (13) (14) . Of note, multiple case reports have documented the coexistence of HS and inflammatory eye diseases (IEDs), including peripheral ulcerative keratitis (PUK) and uveitis . The eye is a commonly affected organ in several systemic inflammatory diseases including Crohn's disease. Given that HS is believed to be a disease with systemic immune dysregulation similar to Crohn's disease, IED may be a rare manifestation of HS. In this study, we sought to investigate the spectrum of IEDs in patients with HS and to describe the extent of eye involvement, diseases associated with IED, and treatment outcomes of IED in patients with HS.
Methods Patients
An electronic search was performed for patients visiting Cleveland Clinic between January 2005 and January 2016 with the International Classification of Diseases (ICD)-9 and 10 codes for HS (705.83) and IED (scleritis, uveitis, iridocyclitis, iritis, keratitis, and conjunctivitis).
This article does not involve any studies with human participants or animals that were performed by any of the authors. For this type of study, a formal consent is not required.
Study factors
A retrospective chart review was performed to identify demographics, IED patterns, associated conditions, treatments, and outcomes.
The remission was defined as inactive IED for at least 3 months without any steroid treatment. Approval from the institutional review board was obtained prior to initiating the study. Descriptive statistical analysis was performed us- 
Results
In total, 483 patients who had ICD-9 codes entered for both HS and any IED were identified. After a careful screening, 436 patients were excluded because of at least one of the following: episcleritis, keratoconjunctivitis, keratitis, conjunctivitis, corneal ulcers, hyphema, vitreous degeneration, vitreous hemorrhage, and retinal neovascularization. Additionally, 27 patients were excluded due to lack of data for re-assessment of IED diagnosis. A total of 20 patients with concomitant IED and HS were identified and included in this study. The study population included 16 female (80%) and 4 male patients (20%) with a majority of them being African American (12 African Americans, seven Caucasians, and one Asian; Table 1 ). HS was diagnosed before the IED in 11 out of 20 patients (55%). The mean age at HS diagnosis was 42.15 years, whereas the mean age at IED diagnosis was 43.65 years.
Out of the 20 patients with concomitant IED-HS, 13 had uveitis (65%), six had scleritis (30%), and one had PUK. Of note, 13 out of the 20 patients (65%) had multiple autoimmune and/ or inflammatory comorbidities (Table 1) . Forty percent of the patients had inflammatory bowel disease (IBD). One patient had both Crohn's disease and psoriasis. Further, two patients had undifferentiated IBD in association with other diseases such as common variable immunodeficiency and lymphoma. Two of the 20 cases (10%) with concomitant IED-HS were diagnosed with rheumatoid arthritis. Other associated diseases included multiple sclerosis in one patient, systemic lupus erythematosus in one patient, and ankylosing spondylitis and common variable immunodeficiency in one patient (Table 1) . Seven patients (35%) did not have any concomitant, comorbid inflammatory/autoimmune condition ( Table 2) .
Most of the patients (85%) were on topical steroids for IED management (Table 3) . Forty percent of them were on tumor necrosis factor (TNF) inhibitors, 35% were on methotrexate, and 35% were on systemic steroids. Intraocular steroid injection was used in one patient (5%). All the cases that were treated with infliximab (3/3) were found to achieve remission. Two out of four cases achieved remission with adalimumab. Two patients on adalimumab did not achieve remission; one patient had to stop the medication due to bacteremia after 1 month, and the other patient had irregular injections and had to stop adalimumab due to financial problems. Systemic steroids, topical steroids, and methotrexate had 14%, 29%, and 29% remission rates, respectively. One patient receiving intraocular steroid injection did not achieve remission (Table 3) .
Discussion
In this study, we demonstrated the spectrum of IEDs that can be encountered in patients with HS. Majority of these patients had other systemic autoimmune and/or inflammatory diseases besides HS that could explain the presence of IED; however, 35% of the patients did not have any other concomitant, chronic systemic disease. We believe that this finding supports the hypothesis of a common pathogenic link between IED and HS.
Uveitis was the most prevalent form of IED in patients with HS, which was followed by scleritis and then PUK. IBD, particularly Crohn's disease, was the most prevalent disease among these patients. As expected, other inflammatory conditions were also seen in this cohort, including sarcoidosis, rheumatoid arthritis, ankylosing spondylitis, and systemic lupus erythematosus, all of which have a clear association with IED. Consistent with our results, HS has been reported to be associated with Crohn's disease in literature (18) . The pathogenic link between the two diseases remains unclear; however, there are some clinical and pathogenic similarities in these diseases. First, the studies performed in patients with familial HS showed impaired Notch signaling, which appears to suppress Toll-like receptor 4-triggered proinflammatory, macrophage cytokine expression, which in turn may explain the excessive proinflammatory cytokine production [TNF-α, interleukin (IL)-1b, and IL-23] seen in some forms of HS (19, 20) . Similarly, the pathogenesis of Crohn's disease involves several hypotheses, including disruption of mucosal barrier with environmental stimuli; activation; proinflammatory cytokine release; and excessive retention of macrophages, neutrophils, and T cells as well as dysbiosis (21) . Clinically, Crohn's disease is a systemic, inflammatory disease with cutaneous, articular, and ocular manifestations. Both HS and Crohn's disease occur in body areas rich in bacteria, are characterized by chronic inflammation, can be treated with antibiotics and TNF inhibitors, and may cause squamous cell carcinoma as a longterm complication. With this study, we showed that IED may be seen in patients with HS, similar to Crohn's disease.
Regarding therapy, topical steroids are typically considered as the first-line treatment for IED. However, in this cohort with HS, most patients did not achieve remission with topical treatment. The escalation of the therapy with systemic immunosuppressive agents was often necessary. The anti-TNF-α therapy is of particular interest considering their higher rate of remission in this study group. Apart from this, several of these patients also experienced an improvement in the HS symptoms with immunosuppressive therapy.
Although our study has some strengths, it also has multiple limitations; our cohort represented a small number of patients, and additional studies with higher number of patients are necessary to confirm the possible association of HS and IED and the long-term outcomes of IED treatment in patients with HS. Secondly, the retrospective nature of this study precluded the documentation of skin response to immunosuppressive medication. Lastly, the low number of patients treated with anti-TNF agents preclude any strong recommendation for these agents in the treatment of IED in patients with HS but do indicate that there is a therapeutic potential in this particular group.
In conclusion, this study expands on previously limited case reports. Ultimately, clinicians should be aware of a possible association between HS and IED, which might also be a manifestation of an immune dysregulation phenomenon. 
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